tbuckley/cabot-search huggingface dataset:
Chronic Lymphocytic Leukemia Subset Expressing Mutated IGHV3-23 Has Peculiar Clinical and Biological Features.
Authors: Riccardo Bomben, Michele Dal-Bo, Dania Benedetti, Daniela Capello, Francesco Forconi, Daniela Marconi, Francesco Bertoni, Rossana Maffei, Luca Laurenti, Davide Rossi, Maria Ilaria Del Principe, Fabrizio Luciano, Elisa Sozzi, Ilaria Cattarossi, Antonella Zucchetto, Francesca Maria Rossi, Pietro Bulian, Emanuele Zucca, Milena Nicoloso, Massimo Degan, Roberto Marasca, Dimitar G Efremov, Giovanni Del Poeta, Gianluca Gaidano, Valter Gattei
Journal: Blood (2009)
Consolidation Therapy with Subcutaneous Alemtuzumab After Induction Treatment with Oral FC (Fludarabine and Cyclophosphamide) in Previously Untreated Patients Aged 65–70 Years with Advanced Stage Chronic Lymphocytic Leukemia (CLL): Final Results of a Phase II Study From the FCGCLL/WM,
Authors: Alain Delmer, Olivier Tournilhac, Stéphane Leprêtre, Bruno Cazin, Pierre Feugier, Brigitte Dreyfus, Beatrice Mahe, Michel Leporrier, Anne-Sophie Michallet, Arnaud Jaccard, Marine Divine, Vincent Levy, Florence Cymbalista, Remi Letestu
Journal: Blood (2011)
Whose research agenda is it? Reconciling the views of researchers and sports stakeholders
Authors: Caroline F Finch
Journal: British Journal of Sports Medicine (2016)

It is now widely recognised that it is important to involve a full range of stakeholders and other research end-users, from the outset when designing and implementing prevention programmes.1 ,2 As long ago as 2003, my team recognised that the views of those actively involved in sport should also be considered when setting research priorities.3 Findings from our survey of coaches and sports administrators have since informed the direction of much of our sports injury research over the following decade in community Australian Football. There will be similar examples from other sports, even if they have not been formally documented in the sports medicine literature.

There is also increasing awareness that sports medicine research evidence is not being widely adopted within many sports settings, and this is limiting the effectiveness of interventions.4 The possible reasons for this are varied, but could include that the interventions and other evidence generated by researchers are not considered to be of enough importance to sport itself …
FRI0016 Regulation of Osteoclast Differentiation by Arginase I
Authors: J. Brunner, M. Hofamann, V. Saferding, K. Redlich, J.S. Smolen, G. Schabbauer, S. Blüml
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Osteoclasts are giant, multi-nucleated cells that derive from the monocyte-macrophage linage and are involved in bone turnover. They are further known as the main effector cells for development of age-related osteoporosis. <h3>Objectives</h3> While the role of Arginase I within certain myeloid lineages such as macrophages is well appreciated, its role within osteoclasts is relatively unknown. Our aim was therefore to investigate the importance of the enzyme in the context of osteoclastogenesis. <h3>Methods</h3> We analyzed osteoclastogenesis of C57BL/6J or BALB/c wildtype cells in vitro in the presence and absence of recombinant Arginase I (recARG1) and its inhibitor nor-NOHA. This was complemented via qPCR analysis of marker genes. We further investigated the potential of the enzyme to induce cell death via flow cytometry analysis of 7-AAD and Annexin V. <h3>Results</h3> In osteoclast differentiation assays, we show that Arginase I is strongly downregulated during osteoclastogenesis, suggesting involvement of this enzyme in OC differentiation. We further show that addition of recArgI completely abolishes osteoclast formation without inducing cell death. The inhibitory effect of recArgI on osteoclastogenesis was completely dependent on the enzymatic function, as no decrease in osteoclast formation could be observed during combined addition of recArgI and its specific inhibitor nor-NOHA. We further demonstrate that recArgI specifically inhibits RANKL-mediated terminal differentiation of OCs, but has no effect on MCSF dependent generation of OC precursors. In line, we could show that addition of recombinant Arginase I negatively regulated the expression of classic RANKL induced osteoclastic marker genes such as TRAP and Cathepsin K. <h3>Conclusions</h3> We propose that recArgI might be a potent inhibitor of osteoclastogenesis and could prove itself to be useful for the treatment of osteoclast driven diseases, such as osteoporosis. <h3>Disclosure of Interest</h3> None declared
Effect of KIR Ligand Mismatched SCT for Infantile ALL with MLL gene Rearrangement: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)
Authors: Takako Miyamura, Masahiro Hirayama, Kanji Sugita, Tomoyuki Watanabe, Eiichi Ishii, Katsuyoshi Koh, Koji Kato, Akiko Moriya Saito, Keizo Horibe, Masahito Tsurusawa, Daisuke Tomizawa
Journal: Blood (2012)
Comment on Crews et al. Role and Determinants of Adherence to Off-loading in Diabetic Foot Ulcer Healing: A Prospective Investigation. Diabetes Care 2016;39:1371–1377
Authors: Jaap J. van Netten, Peter A. Lazzarini, Sicco A. Bus
Journal: Diabetes Care (2016)

We read with great interest the article by Crews et al. (1), which investigated the role and determinants of adherence to off-loading in diabetic foot ulcer healing. The authors found that greater off-loading adherence contributes to better ulcer outcomes and that postural instability is a key barrier to nonadherence. As the authors rightly stress, adherence to wearing an off-loading device is considered of great clinical importance; yet, research to substantiate this has been lacking. We congratulate the authors on this important study and particularly their use of a validated method to measure adherence. However, we want to address three aspects that limit broader interpretation.

First, the primary clinical outcome chosen was ulcer …
Hydrocortisone does Not Influence in Vitro Glucocorticoid Sensitivity of Acute Lymphoblastic Leukemia Blasts
Authors: Lidewij T. Warris, Marry M. van den Heuvel-Eibrink, Ingrid M. Ariës, Rob Pieters, Erica L.T. van den Akker, Monique L. Den Boer
Journal: Blood (2014)
AB0286 Ultrasound Defined Remission in Tunisian Rheumatoid Arthritis: Table 1.
Authors: S. Miladi, K. Ben Abdelghani, L. Souabni, S. Kassab, S. Chekili, A. Laatar, L. Zakraoui
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Remission is the principal purpose of treatment in rheumatoid arthritis (RA). Different scores and indices are available to define remission. However, even when the most stringent ones are used, structural damages can occur. The Ultrasonography (US) and especially Power Doppler seems to be the best way to assess true remission and avoid future disabilities. <h3>Objectives</h3> To assess the association of clinical and/or serological parameters with ultrasound defined remission in RA. <h3>Methods</h3> A prospective study of 68 Tunisian RA patients was performed. US examination was performed by an experienced rheumatologist blinded to the statue of activity of RA. For each patient 22 joints were scanned: wrists, metacarpo-phalangeal, and proximal interphalangeal joints. A binary score (absence or presence) of synovial hypertrophy/effusion (SH) and power Doppler (PD) signals was applied for each joint. The Sonographic Remission was defined by the absence of PD signals. Visual analogic scale of pain (VAS), Global assessment of disease activity by the patient (GAP), duration of morning stiffness (MS), number of night awakening (NA), tender joint count (TJC), swollen joint count (SJC), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and health assessment questionnaires (HAQ) were recorded and compared between patients who were in Sonographic Remission (G1) or not (G2). <h3>Results</h3> Over the 68 patients recruited, 85% were females. The mean age was 50 years-old [30-70]. Among patients, 30 were diagnosed in remission according to the Disease Activity Score 28 joints and only 13 of them were in remission according to ultrasound. PD signals as a sign of active disease were observed in 53 (78%) patients. Main results are presented in table 1. VAS, GAP and CRP were significantly higher in G2 than in G1. <h3>Conclusions</h3> According to our study, sonography-defined disease activity is associated with VAS, GAD and CRP. VAS and GAD, although usually considered as subjective criteria, seem useful for evaluating RA remission. <h3>References</h3> Vasanth LC. Imaging of rheumatoid arthritis. Rheum Dis Clin North Am 2013 <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5159
Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM).
Authors: Martha Raschko, Stephanie Markovina, Shigeki Miyamoto, Walter Longo, Eliot Williams, Thomas McFarland, Jae Werndli, Elisabeth Wagner, Mark Juckett, Natalie Callander
Journal: Blood (2007)
Reversible Expansion of Hematopoietic Stem Cells (HSC) and CML-Like Disease in Transgenic Mice Expressing BCR-ABL under the Control of the SCL 3′ Enhancer.
Authors: Steffen Koschmieder, Berthold Goettgens, Pu Zhang, Tajhal Dayaram, Kristin Geary, Anthony R. Green, Daniel G. Tenen, Claudia S. Huettner
Journal: Blood (2004)
Skewed TCR Repertoire of Vδ1+ γδT Cells in Recipients of Allogeneic Hematopoietic Stem Cell Grafts and Possible Involvement of Epstein-Barr Virus in Clonal Expansion of Vδ1+ T Cells.
Authors: Masumi Fujishima, Makoto Hirokawa, Naohito Fujishima, Hirobumi Saitoh, Yoshikazu Ichikawa, Yoshinari Kawabata, Ikuo Miura, Ken-ichi Sawada
Journal: Blood (2004)
High Rates of Early Donor Chimerism in Intermediate and Poor Risk Patients Undergoing Stem Cell Transplantation Using Reduced Toxicity Ablative Conditioning Regimen Incorporating Busulfan Pharmacokinetics
Authors: Shatha Farhan, Edward Peres, Danielle Pelland, Susan Wautelet, Klodiana Neme, Nancy Mikulandric, Kenneth Ruemenapp, Mary Ann Trapp, Sarah Szymanski, Nalini Janakiraman
Journal: Blood (2014)
Magnetic mesoporous nanospheres anchored with LyP-1 as an efficient pancreatic cancer probe
Authors: Yongjian Jiang, Shaojun Liu, Yu Zhang, Hengchao Li, Hang He, Juntao Dai, Tao Jiang, Weihang Ji, Daoying Geng, Ahmed A. Elzatahry, Abdulaziz Alghamdi, Deliang Fu, Yonghui Deng, Dongyuan Zhao
Journal: Biomaterials (2016)
Early Bortezomib Following Allogeneic Stem Cell Transplantation (SCT) for Multiple Myeloma To Enhance or Maintain Remission Status.
Authors: Nicolaus Kroeger, Tatjana Zabelina, Francis Ayuk, Djordje Atanackovic, Heike Schieder, Helmut Renges, Axel R. Zander
Journal: Blood (2005)
OP0282 Expression of Vitamin D Receptor Associated Genes in The Aorta of Coronary Artery Disease Patients with and without Rheumatoid Arthritis
Authors: I. Oma, J.K. Andersen, S. Holm, O.K. Olstad, I. Fostad, T. Lyberg, S.M. Almdahl, Ø. Molberg, I. Hollan
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Vitamin D has an important role in the immune system, and has been linked to inflammation, rheumatoid arthritis (RA) and coronary artery disease (CAD)[1, 2]. However, the exact mechanisms how vitamin D is involved in these processes are still unclear. <h3>Objectives</h3> To compare expression of vitamin D receptor (VDR) associated genes in the aortic adventitia of CAD patients with and without RA. <h3>Methods</h3> RNA was isolated, and Affymetrix microarray was used to determine the gene expression profile in specimens from the ascending aorta in 8 patients with CAD and 8 patients with CAD and RA from the Feiring Heart Biopsy Study. Partek Genomics Suite software was used to identify differentially expressed genes by one-way ANOVA (<i>p</i>&lt;0.05; FC&gt;1.1), and differences in expression of VDR associated genes were determined by Ingenuity Pathway Analysis. <h3>Results</h3> Among the 15586 transcripts that were identified, pathway analysis determined two genes within the VDR signaling pathway, Growth arrest and DNA-damage-inducible protein 45 alpha (GADD45A) (<i>p</i>=0.006; FC=1.474) and Nuclear Receptor Corepressor 1 (NCOR1) (<i>p</i>=0.005; FC=1,210), that where both up-regulated in RA patients. <h3>Conclusions</h3> We found that GADD45A and NCOR1 were upregulated in the aorta of RA patients. GADD45A induces cell cycle arrest, DNA repair and apoptosis in response to various environmental stresses [3], while NCOR1 has an important role as a gene-specific integrator of positive and negative signals that control inflammation [4]. Based on this finding, we hypothesize that the accelerated atherosclerosis in RA might be related to the up-regulation of GADD45A and NCOR1 through the VDR signaling pathway. <h3>References</h3> Urruticoechea-Arana A, Martin-Martinez MA, Castaneda S, Piedra CA, Gonzalez-Juanatey C, Llorca J et al. Vitamin D deficiency in chronic inflammatory rheumatic diseases: results of the cardiovascular in rheumatology [CARMA] study. Arthritis Res Ther 2015;17: 211. Norman PE, Powell JT. Vitamin D and cardiovascular disease. Circ Res 2014;114 2: 379–93. Rosemary Siafakas A, Richardson DR. Growth arrest and DNA damage-45 alpha (GADD45alpha). The international journal of biochemistry &amp; cell biology 2009;41 5: 986–9. Glass CK, Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 2010;10 5: 365–76. <h3>Disclosure of Interest</h3> None declared
High Response Rate of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Updates of Phase I Trial
Authors: Dai Chihara, Yasuhiro Oki, Jason R Westin, Loretta Nastoupil, Luis E. Fayad, Felipe Samaniego, Emily Wesson, Charnelle Ruben, Sandra B. Horowitz, Lei Feng, Naveen Garg, Sairah Ahmed, Issa F. Khouri, Chitra M. Hosing, Jorge E. Romaguera, Nathan Fowler, Michelle A. Fanale
Journal: Blood (2015)
Genetic and Epigenetic Regulation of the Gamma Globin Locus Is Associated with Fetal Hemoglobin Levels and Frequency of Pain in Sickle Cell Disease
Authors: Blair Anderson, Ebenezer Enchia, Karen Soldano, Melanie Garrett, Jude Jonassaint, Laura M. De Castro, Marilyn J. Telen, Allison E Ashley-Koch
Journal: Blood (2012)
TET2 Favors Mesoderm and Hematopoietic Differentiation in Human Embryonic Stem Cells
Authors: Barbara da Costa Reis Monte Mor, Thierry Langlois, Nathalie Droin, Elodie Pronier, Jean-Pierre Le Couédic, Nathalie Auger, Carole Almire, Thomas Mercher, Francois Delhommeau, Debili Najet, Olivier Bernard, Eric Solary, Isabelle Plo, William Vainchenker
Journal: Blood (2011)
PTU-151 Predicting 30-Day Mortality and Re-Stenting Following Self Expanding Metal Stent (SEMS) Insertion for The Palliation of Dysphagia in Patients with Oesophageal Cancer
Authors: J Sterne, J Macdonald, P Phull, J Leeds
Journal: Gut (2016)

<h3>Introduction</h3> Management of dysphagia due to malignant obstruction of the oesophagus can be challenging. Endoscopically placed self-expanding metal stents (SEMS) remain an important tool and have been performed under direct vision in our institution since 2004. A previous audit suggested a significant morbidity and mortality rate and therefore the aim of this study was to identify risk factors for 30 day mortality and re-intervention. <h3>Methods</h3> A retrospective review of all patients undergoing oesophageal SEMS insertion was performed over the period 2004–2014. Data collected included patient demographics, tumour stage/position, stent type inserted, survival following SEMS insertion, bioprofile and other therapies. Univariate analysis was performed and was followed by multivariate logistic regression to identify independent variables associated with 30 day mortality and re-stenting. <h3>Results</h3> 396 patients (median age 74 years, 252 males) had 514 stents were inserted over the study period and were included in the study. Regarding 30 day mortality, univariate analysis showed association with distal tumours (OR 1.6), stent length &gt;10 cm (OR 3.0), oncological treatment (OR 0.4), raised CRP (OR 6.1), raised white cell count (OR 6.0), anaemia (OR 2.8) and low albumin (OR 4.9). Multivariate analysis showed white cell count (OR 8.1, 2.0–21.9, p &lt; 0.001, albumin &lt;35 g/l (OR 6.9, 2.6–18.8, p &lt; 0.001) and oncological treatment (OR 0.3, 0.1–0.8, p = 0.013) were independent predictors of 30 day mortality. Regarding re-intervention, univariate analysis showed association with age &gt; 70 (OR 0.6), junctional tumours (OR 0.5), stent length &gt;10 cm (OR 0.6), raised CRP (OR 0.5) and raised white cell count (OR 0.4). Multivariate analysis showed age &gt; 70 (OR 0.5, 0.3–0.9, p = 0.032) and raised white cell count (OR 0.4, 0.2–0.8, p = 0.009) were independent predictors of re-intervention. <h3>Conclusion</h3> Raised inflammatory markers were associated with poorer outcomes following oesophageal SEMS insertion and oncological treatment was protective. Longer survival appears to be associated with re-intervention following initial stent insertion. This data may provide a framework for the creation of a prognostic scoring system prior to SEMS insertion. <h3>Disclosure of Interest</h3> None Declared
Prolonged Administration of Hydroxyurea Reduces Morbidity and Mortality in Adult Patients with Sickle-Cell Syndromes: Long-Term Experience of a Single Center.
Authors: Ersi Voskaridou, Antonios Bilalis, Dimitrios Christoulas, Konstantinos Varvagiannis, Kleio Sinopoulou, Eleni Plata, Panagiotis Tsaftaridis, Dimitris Loukopoulos, Evangelos Terpos
Journal: Blood (2008)
Structural Changes in the Internal Domain of CD20 Antigen Associated with the Emergence of Rituximab Resistance: Effects of Proteasome Inhibition in CD20 Structure and Rituximab Anti-Tumor Activity in Rituximab-Resistant Cell Lines (RRCL).
Authors: Francisco J. Hernandez-Ilizaliturri, Scott H. Olejniczak, Joy Knight, Myron S. Czuczman
Journal: Blood (2005)
Lymphoid Microenvironment Inhibits Apoptosis in B-CLL Cells: Involvement of PI3-K/AKT Pathway and PTEN.
Authors: Medhat Shehata, Susanne Schnabl, Dita Demirtas, Josef D. Schwarzmeier, Martin Hilgarth, Markus Duechler, Alexander Gaiger, Rainer Hubmann, Ulrich Jaeger
Journal: Blood (2006)
AB0491 Pleural and Pulmonary Involvements in Systemic Lupus Erythematous
Authors: T. Ben Salem, I. Naceur, M. Tougorti, M. Lamloum, M. Khanfir, I. Ben Ghorbel, M.H. Houman
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Pleural and pulmonary involvements (PPI) occur in almost half of the patients with systemic lupus erythematous (SLE). The aim of the study was to determine prevalence of these manifestations in a group of Tunisian SLE patients and to describe their clinical, biological, and immunological characteristics. <h3>Methods</h3> We conducted a retrospective study of patients who fulfilled the revised ACR criteria of SLE admitted in an Internal Medicine department over a period time of 14 years. Patients with PPI related to SLE were included. Infectious states were excluded. Respiratory involvements were evaluated using chest x-ray, computed tomography (CT) and pulmonary function tests. <h3>Results</h3> Sixty six SLE patients had PPI (27%). The mean age was 36 years (ranges 14 to 69 years). The sex-ratio M/F was 0.1. Clinical symptoms were dyspnea (6 cases), chest pain (4 cases) and fever (32 cases). The chest X-Ray was abnormal in 66 cases: pleural effusion (n=65), atelectasis (n=2) and parenchymal opacities (n=1). CT showed parenchymal bands in three cases and fluctuating multifocal opacities in one patient. Pleural fluid was lymphocytic in all cases. Pulmonary function tests showed restrictive syndrome in two cases. PPI was found in 44 cases (67%) at the time of SLE diagnosis and revealed the disease in 18 cases. In other cases, PPI occurred after mean disease duration of 44 months. Pleural effusion was confirmed in 65 patients. Two patients had Shrinking syndrome. Bronchiolitis obliterans was diagnosed in one patients and organizing pneumonia in another one. Pulmonary hypertension was noted in 4 patients. Other involvements were noted in all patients: pericardial effusion (77%), cutaneaous manifestations (74%), lupus nephritis (36%), neurological involvements (14%) and myositis (9%). Comparison of patients with and without PPI involvements showed that pericarditis was significantly more frequent in patients with PPI (76.2% vs 22.6%; p&lt;0.001). Antibodies to extractable antigens and anti-SSB/La antibodies were more frequent in these patients (94% vs 82.6%; p=0.049 and 57.9% vs 28.4%; p=0.001 respectively). Patients received steroids and immunosuppressant drugs in 88% and 51% of cases respectively. Pleural effusion was recurrent in 7 patients. Mean duration of follow up was 69 months (range 0–187). <h3>Conclusions</h3> SLE had a wide spectrum pulmonary manifestations; pleural effusion is the most frequent. PPI can be due to lupus itself or to other associated conditions. In all cases, possible infectious and drug-induced causes should be ruled out. <h3>Disclosure of Interest</h3> None declared
Pro–angiogenic Induction of Myeloid Cells for Therapeutic Angiogenesis Can Favor MAPK p38–dependent Foam Cell Formation
Authors: Eva Rohde, Katharina Schallmoser, Andreas Reinisch, Nicole A Hofmann, Thomas Pfeifer, Gerald Rechberger, Dagmar Kratky, Eleonore Fröhlich, Dirk Strunk
Journal: Blood (2010)
Recombinant Human Mannose-Binding Lectin (rhMBL) Binds to Human and Mouse Cancer Cells and Elicits Antitumor Activity in a MBL Knockout Mouse Model of Murine Cancer.
Authors: Puja Sapra, Patricia Kraft, Mary Mehlig, Zhihua Zhang, Lee M. Greenberger, Ivan D. Horak
Journal: Blood (2006)
Pulsed Low Dose Intravenous Melphalan in Patients with AL Amyloidosis, Ineligible for Aggressive Treatment with High-Dose Melphalan and Stem Cell Transplantation.
Authors: Vaishali Sanchorawala, David C. Seldin, Daniel G. Wright, Martha Skinner, Kathleen T. Finn, Rodney H. Falk
Journal: Blood (2004)